VALANBIO THERAPEUTICS
Valanbio Therapeutics is an early-stage anti-infectives company that develops novel antibiotics for Gram-negative organisms. It is based in Raleigh, North Carolina.
VALANBIO THERAPEUTICS
Industry:
Biotechnology Health Care Lifestyle Therapeutics
Founded:
2015-01-01
Address:
Raleigh, North Carolina, United States
Country:
United States
Total Employee:
11+
Status:
Active
Contact:
(919) 389-1301
Total Funding:
421 K USD
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Aviceda Therapeutics
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Current Employees Featured
More informations about "Valanbio Therapeutics"
Valanbio Therapeutics - Crunchbase Company Profile & Funding
Valanbio Therapeutics is an early-stage anti-infectives company that develops novel antibiotics for Gram-negative organisms.See details»
Valanbio Therapeutics Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Valanbio Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Valanbio Therapeutics - Funding, Financials, Valuation & Investors
Valanbio Therapeutics is an early-stage anti-infectives company that develops novel antibiotics for Gram-negative organisms.See details»
Targeting tough bacteria: Durham biotech startup …
Aug 16, 2023 · Consider Durham-based anti-infectives startup ValanBio Therapeutics. The journey that led to the development of its new synthetic antibiotic technology – LPC-233 – began about 40 years ago. And...See details»
Synthetic Antibiotic Could Be Effective Against Drug …
There are multiple patents being filed on the series of compounds, and Toone and Zhou have co-founded a company called Valanbio Therapeutics, Inc. which will be looking for partners to bring LPC-233 through phase 1 clinical trials to …See details»
VALANBIO THERAPEUTICS, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for VALANBIO THERAPEUTICS, INC. of Raleigh, NC. Get the latest business insights from Dun & Bradstreet.See details»
Valanbio Therapeutics Inc - VentureRadar
Valanbio Therapeutics is located in Raleigh and is developing novel antibiotics for Gram-negative organisms. For example the company is studying the potent LpxC inhibitor LPC-233 as a …See details»
ValanBio Therapeutics Inc. | North Carolina Biotech Center
Valanbio Therapeutics is an early-stage anti-infectives company. Valanbio is developing novel antibiotics for Gram-negative organisms.See details»
Valanbio Therapeutics - Contacts, Employees, Board Members
Valanbio Therapeutics has 2 current employee profiles, including Chairman & Board of Directors Moise Khayrallah. Valanbio Therapeutics is an early-stage anti-infectives company that …See details»
Duke researchers develop potent antibiotic against drug-resistant …
Aug 9, 2023 · A scientific journey decades in the making at Duke University has found a new antibiotic strategy to defeat gram-negative bacteria like Salmonella, Pseudomonas and E. coli, …See details»
ValanBio Developing New Synthetic Antibiotic to Treat Urinary …
Aug 15, 2023 · Consider Durham-based anti-infectives startup ValanBio Therapeutics. The journey that led to the development of its new synthetic antibiotic technology – LPC-233 – …See details»
Targeting tough bacteria: Durham biotech startup advances …
Aug 17, 2023 · Consider Durham-based anti-infectives startup ValanBio Therapeutics. The journey that led to the development of its new synthetic antibiotic technology – LPC-233 – …See details»
Decades in the Making – New Synthetic Antibiotic Could Defeat …
Aug 11, 2023 · There are multiple patents being filed on the series of compounds, and Toone and Zhou have co-founded a company called Valanbio Therapeutics, Inc. which will be looking for …See details»
Synthetic antibiotic could be effective against drug-resistant ...
Aug 9, 2023 · A scientific journey decades in the making at Duke University has found a new antibiotic strategy to defeat gram-negative bacteria like Salmonella, Pseudomonas and E. coli, …See details»
Synthetic antibiotic shows 'potent' efficacy against superbugs
Aug 14, 2023 · Zhou and his team have patented the drug and spun out a startup, Valanbio Therapeutics, to take it to the clinic. Bacteria fall into two broad categories based on the …See details»
Synthetic Antibiotic Could Be Effective Against Drug-Resistant ...
Aug 9, 2023 · There are multiple patents being filed on the series of compounds, and Toone and Zhou have co-founded a company called Valanbio Therapeutics, Inc. which will be looking for …See details»
SBIR-STTR Award - inknowvation.com
Valanbio Therapeutics seeks to address this urgent unmet public need by developing novel antibiotics targeting the essential enzyme LpxC in Gram-negative bacteria.See details»
IND-enabling studies of the potent LpxC inhibitor LPC-233 as a …
Apr 16, 2020 · Valanbio Therapeutics seeks to address this urgent unmet public need by developing novel antibiotics targeting the essential enzyme LpxC in Gram-negative bacteria.See details»
Preclinical safety and efficacy characterization of an LpxC inhibitor ...
Aug 9, 2023 · It is orally bioavailable and efficiently eliminates infections caused by susceptible and multidrug-resistant Gram-negative bacterial pathogens in murine soft tissue, sepsis, and …See details»